Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells-Reference-Cited by-同舟云学术

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

Published:2007-08-24 Issue:3 Volume:57 Page:411-423
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Müller Tina,Uherek Christoph,Maki Guitta,Chow Kai Uwe,Schimpf Annemarie,Klingemann Hans-Georg,Tonn Torsten,Wels Winfried S.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-007-0383-3.pdf

Reference49 articles.

1. Maloney DG (2005) Immunotherapy for non-Hodgkin’s lymphoma: monoclonal antibodies and vaccines. J Clin Oncol 23:6421–6428

2. Cartron G, Watier H, Golay J, Solal-Celigny P (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood 104:2635–2642

3. Schilling V (2003) Immunotherapy with anti-CD20 compounds. Semin Cancer Biol 13:211–222

4. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457–2466

5. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188–2195

Cited by 187 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery;Journal of Nanobiotechnology;2024-09-10

2. CAR-NK Cells as Promising Immune Therapeutics: Platforms and Current Progress;International Journal of Cancer Management;2024-05-01

3. Nanobody-based CAR NK cells for possible immunotherapy of MICA+ tumors;PNAS Nexus;2024-04-30

4. A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseases;Medical Oncology;2024-04-24

5. Chimeric antigen receptor engineered natural killer cells for cancer therapy;Experimental Hematology & Oncology;2023-08-10